Indivior Pharmaceuticals (INDV) Non-Current Debt (2021 - 2026)

Indivior Pharmaceuticals' Non-Current Debt history runs 6 years deep, the most recent figure standing at $486.0 million for Q1 2026.

• In Q1 2026, Non-Current Debt rose 56.27% year-over-year to $486.0 million; the TTM figure through Mar 2026 stood at $486.0 million (up 56.27% YoY), while the FY2025 annual figure was $290.0 million, down 7.94% from the prior year.
• Non-Current Debt was $486.0 million for Q1 2026 at Indivior Pharmaceuticals, up from $290.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $486.0 million in Q1 2026 to a low of $237.0 million in Q4 2022.
• Historically, Non-Current Debt has averaged $311.0 million across 5 years, with a median of $306.0 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Debt retreated 7.94% in 2025, then jumped 56.27% in 2026.
• A 5-year view of Non-Current Debt shows it stood at $237.0 million in 2022, then changed by 0.0% to $237.0 million in 2023, then soared by 32.91% to $315.0 million in 2024, then declined by 7.94% to $290.0 million in 2025, then soared by 67.59% to $486.0 million in 2026.
• The last three Non-Current Debt figures came in at $486.0 million (Q1 2026), $290.0 million (Q4 2025), and $304.0 million (Q3 2025), per Business Quant data.